News Conference News ESC 2025 PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy Michael O'Riordan September 01, 2025
News Conference News ESC 2025 MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide Caitlin E. Cox August 30, 2025
News Conference News AHA 2024 SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity Michael O'Riordan November 16, 2024
News Conference News ESC 2024 ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions Michael O'Riordan September 17, 2024
News Conference News ESC 2024 MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority Shelley Wood September 01, 2024
News Conference News ACC 2024 ADHD Meds Linked to Cardiomyopathy in Young Adults Todd Neale April 01, 2024
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022
News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ESC Heart Failure 2021 IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients Shelley Wood June 30, 2021
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Conference News HFSA 2020 Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study L.A. McKeown October 12, 2020